Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Covidien Combination Product to Treat Spasticity The U.S. Food and Drug Administration - Medical Product Outsourcing

FDA Approves Covidien Combination Product to Treat Spasticity The U.S. Food and Drug Administration

FDA Approves Covidien Combination Product to Treat Spasticity
The U.S. Food and Drug Administration has approved Covidien plc’s Gablofen prefilled syringes. Gablofen (a brand name of baclofen) is primarily used to treat spasticity and is in the early research stages for use for the treatment of alcoholism. The prefilled syringes reportedly are designed to cut down on preparation time and make it easier for patients on intrathecal (when a drug is introduced under the arachnoid membrane of the brain or spinal cord) Baclofen therapy. Gablofen is specifically targeted at spasticity traced to spinal and cerebral causes, and is marketed under Covidien’s pharmaceuticals brand Mallinckrodt. Prefilled syringes of Gablofen will be marketed beginning in February. It will be sold in vials of various concentrations.

Covidien is headquartered in Dublin, Ireland. The firm’s U.S. base is in Mansfield, Mass. The company has been quite acquisitive in the past year, scooping up several companies with the aim of diversification and development of new products and technologies. In October last year, Covidien’s pharmaceuticals business Mallinckrodt acquired CNS Therapeutics Inc., a St. Paul Minn.-based specialty pharmaceutical company, for approximately $100 million. Covidien plans to spin-off its pharmaceutical business by mid-2013 to focus on its high-margin surgical products portfolio.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters